RARE and MREO Related Headlines
Go Back- Leerink on Ultragenyx Pharma (RARE): 'DTX401 Rolling BLA Submitted, Setting Up Launch for Underappreciated Program'
- Ultragenyx Pharma (RARE) PT Lowered to $63 at Jefferies
- Jefferies Downgrades Mereo BipPharma Group (MREO) to Hold
- Ultragenyx Pharma (RARE) PT Lowered to $70 at Leerink Partners
- Mereo BipPharma Group (MREO) PT Lowered to $2 at Leerink Partners
- LifeSci Capital Downgrades Mereo BipPharma Group (MREO) to Market Perform
- Ultragenyx Pharma (RARE) PT Lowered to $47 at Baird
- Ultragenyx Pharma (RARE) PT Lowered to $50 (from $103) at Citi
- William Blair Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
- Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
- BTIG Reiterates Buy Rating on Mereo BipPharma Group (MREO)
- Ultragenyx and Mereo advance UX143 osteogenesis imperfecta study to final analysis
- Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
